Equities

Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals PLC

Actions
  • Price (EUR)7.10
  • Today's Change-0.150 / -2.07%
  • Shares traded0.00
  • 1 Year change358.06%
  • Beta1.3721
Data delayed at least 15 minutes, as of May 29 2020 07:08 BST.
More ▼

Profile data is unavailable for this security.

About the company

Avadel Pharmaceuticals plc is a biopharmaceutical company. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. It is developing Akovaz, Bloxiverz, Vazculep and Nouress, which are sterile injectable drugs used in the hospital setting. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.

  • Revenue in USD (TTM)55.02m
  • Net income in USD-30.20m
  • Incorporated2017
  • Employees50.00
  • Location
    Avadel Pharmaceuticals PLCBlock 10-1 Blanchardstown Corporate ParkBallycoolinDUBLIN 15IrelandIRL
  • Phone+353 14851200
  • Fax+353 15261077
  • Websitehttps://www.avadel.com/
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.